ECM
DFTX

ExodusPoint Capital Management’s Definium Therapeutics DFTX Stock Holding History

ExodusPoint Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Buy
104,915
+85,967
+454% +$1.46M 0.02% 786
2025
Q4 		$254K Buy
+18,948
New +$234K ﹤0.01% 1348
2025
Q3 		– Sell
-17,877
Closed -$116K – 1842
2025
Q2 		$116K Buy
+17,877
New +$118K ﹤0.01% 1348

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ExodusPoint Capital Management's DFTX Position: Q1 2026 in Review

ExodusPoint Capital Management increased its Definium Therapeutics (DFTX) stake by 454% in Q1 2026, buying an estimated $1.46M and bringing the position to 104,915 shares worth $1.98M. The position accounts for 0.02% of the portfolio, ranked #786.

ExodusPoint Capital Management first reported a position in DFTX in Q2 2025 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • ExodusPoint Capital Management held 104,915 shares of Definium Therapeutics worth $1.98M as of Q1 2026.
  • ExodusPoint Capital Management bought 85,967 Definium Therapeutics shares in Q1 2026, an estimated $1.46M.
  • Definium Therapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #786 holding.
  • ExodusPoint Capital Management first reported a position in Definium Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.